Adaptimmune Therapeutics PLC (ADAP) Operating Income (Loss) USD 2015 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Adaptimmune Therapeutics PLC quarterly/annual Operating Income (Loss) history and growth rate from 2015 to 2024.
  • Adaptimmune Therapeutics PLC Operating Income (Loss) for the quarter ending March 31, 2024 was -$49.3 M, a 3075% decline year-over-year.
  • Adaptimmune Therapeutics PLC Operating Income (Loss) for the twelve months ending March 31, 2024 was -$191 M, a 69.7% decline year-over-year.
  • Adaptimmune Therapeutics PLC annual Operating Income (Loss) for 2023 was -$140 M, a 14.8% increase from 2022.
  • Adaptimmune Therapeutics PLC annual Operating Income (Loss) for 2022 was -$164 M, a 1.06% decline from 2021.
  • Adaptimmune Therapeutics PLC annual Operating Income (Loss) for 2021 was -$162 M, a 21.6% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$191 M -$49.3 M -$50.9 M -3075% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$140 M -$49.9 M -$22.6 M -83% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-06
Q3 2023 -$117 M -$46.6 M -$3.64 M -8.47% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-08
Q2 2023 -$113 M -$44.9 M -$1.16 M -2.64% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-09
Q1 2023 -$112 M $1.66 M +$51.6 M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$164 M -$27.2 M +$15.6 M +36.4% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-06
Q3 2022 -$180 M -$43 M -$809 K -1.92% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 -$179 M -$43.8 M -$4.44 M -11.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 -$174 M -$50 M -$12.1 M -31.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 -$162 M -$42.9 M -$5.35 M -14.3% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-06
Q3 2021 -$157 M -$42.2 M -$6.31 M -17.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$151 M -$39.3 M -$9.06 M -29.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$142 M -$37.9 M -$8.13 M -27.3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 -$133 M -$37.5 M -$7.16 M -23.6% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-06
Q3 2020 -$126 M -$35.9 M +$4.25 M +10.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$130 M -$30.3 M +$5.25 M +14.8% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$136 M -$29.8 M +$4.03 M +11.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$140 M -$30.4 M +$1.41 M +4.44% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-14
Q3 2019 -$141 M -$40.1 M -$47.1 M -672% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$94 M -$35.5 M -$6.63 M -22.9% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$87.4 M -$33.8 M -$5.05 M -17.6% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q4 2018 -$82.4 M -$31.8 M -$2.07 M -6.96% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-25
Q3 2018 -$80.3 M $7.02 M +$12 M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-06
Q2 2018 -$92.3 M -$28.9 M -$5.1 M -21.4% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-01
Q1 2018 -$87.2 M -$28.7 M -$6.52 M -29.3% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-06
Q4 2017 -$80.7 M -$29.7 M -$15 M -103% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-27
Q3 2017 -$65.6 M -$4.96 M +$13.7 M +73.4% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-06
Q2 2017 -$79.3 M -$23.8 M -$1.08 M -4.76% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 -$78.2 M -$22.2 M -$5.4 M -32.1% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 -$72.8 M -$14.7 M Oct 1, 2016 Dec 31, 2016 10-K 2019-02-27
Q3 2016 -$18.6 M -$10.3 M -124% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-02
Q2 2016 -$22.7 M -$11.6 M -104% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-03
Q1 2016 -$16.8 M -$11.2 M -200% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q3 2015 -$8.31 M Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-10
Q2 2015 -$11.1 M Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-08
Q1 2015 -$5.61 M Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.